ClinicalTrials.gg
CompletedNCT00863551Updated Feb 26, 2016Results posted

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

A Phase 4 interventional study of Trospium Chloride in Elderly, Pharmacokinetics and Overactive Bladder, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 65 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-26.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
65 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Urinary Bladder, Overactive by AbbVie — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · AbbVie.

Enrollment
22nd of 22
12 · median 265
Started
2009
with 4 others
Phase 4
9 of 28
none open now
Registered
9th of 28
by date

Among the 28 studies in Urinary Bladder, Overactive by AbbVie, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2009, is one of 9 in phase 4, and was the 9th registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

None of the 28 studies in Urinary Bladder, Overactive by AbbVie is open now. The open studies under Urinary Bladder, Overactive, anywhere →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 65 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Urinary Bladder, Overactive by AbbVie as a file.
02

Study summary

This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.

03

Conditions studied

  • Elderly
  • Pharmacokinetics
  • Overactive Bladder
04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 65-75 years of age without evidence of memory impairment
  • Subject has overactive bladder symptoms but otherwise healthy
  • Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit)
  • Weight within normal range
  • Ability to follow study instructions and likely to complete all required visits

Exclusion criteria

Exclusion Criteria:

  • Residual urine within bladder greater than 4 ounces
  • Moderate or severe memory impairment
  • Bleeding disorder
  • Blood-thinning agents
  • Concurrent overactive bladder medication
  • Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), galantamine or similar drugs for dementia
  • Chronic kidney failure
  • Abdominal bypass surgery for obesity
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Trospium Chloride Extended Release, 60 mg

    Trospium Chloride Extended Release, 60 mg

    Drug: Trospium Chloride

Interventions

  • Extended release, 60 mg, oral daily

    Also known as: Sanctura XR™ 60 mg

06

What researchers measure

Primary outcomes

  1. Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5

    Cerebral spinal fluid levels of Trospium at day 10, hour 5. Cerebral spinal fluid was collected from each patient.

    Time frame: Day 10, Hour 5

Secondary outcomes

  1. Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose

    The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory).

    Time frame: Day 10

  2. Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose

    The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The delayed recall score provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory).

    Time frame: Day 10

  3. Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-Dose

    The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.

    Time frame: Day 10

  4. Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-Dose

    The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and a yes/no delayed recognition trial. The delayed recall score, derived from the delayed recall trial, provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.

    Time frame: Day 10

07

Results

Posted Dec 19, 2011
Limitations and caveats
Due to technical problems associated with the administration of the BVMT-R test, the results were invalid, therefore, results for Outcome Measures 4 and 5 are not presented.

Participant flow

Participant flow — Overall Study
MilestoneTrospium Chloride Extended Release, 60 mg
Started12
Completed12
Not completed0

Outcome measures

PrimaryCerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5

Cerebral spinal fluid levels of Trospium at day 10, hour 5. Cerebral spinal fluid was collected from each patient.

Time frame:
Day 10, Hour 5
Reported as:
Mean · Picograms per milliliter (pg/mL)
Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5
Picograms per milliliter (pg/mL)Trospium Chloride Extended Release, 60 mg
Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5NA ± NA
SecondaryPercentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory).

Time frame:
Day 10
Reported as:
Number · Percentage of Subjects
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose
Percentage of SubjectsTrospium Chloride Extended Release, 60 mg
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose100
SecondaryPercentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The delayed recall score provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory).

Time frame:
Day 10
Reported as:
Number · Percentage of Subjects
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose
Percentage of SubjectsTrospium Chloride Extended Release, 60 mg
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose91.7
SecondaryPercentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-Dose

The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.

Time frame:
Day 10
Reported as:
Number · Percentage of Subjects
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-Dose
Percentage of SubjectsTrospium Chloride Extended Release, 60 mg
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-DoseNA
SecondaryPercentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-Dose

The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and a yes/no delayed recognition trial. The delayed recall score, derived from the delayed recall trial, provides a measure of the patient's recent memory. The total score ranges from 0 (no memory) to 12 (best memory). Due to technical problems associated with the administration of the test, the results were invalid.

Time frame:
Day 10
Reported as:
Number · Percentage of Subjects
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-Dose
Percentage of SubjectsTrospium Chloride Extended Release, 60 mg
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-DoseNA

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trospium Chloride Extended Release, 60 mg—0/12 (0%)10/12 (83.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTrospium Chloride Extended Release, 60 mg
HeadacheNervous system disorders7/12
NauseaGastrointestinal disorders3/12
VomitingGastrointestinal disorders3/12
ConstipationGastrointestinal disorders2/12
Dry MouthGastrointestinal disorders2/12
FlatulenceGastrointestinal disorders2/12
Low back painMusculoskeletal and connective tissue disorders2/12
FolliculitisSkin and subcutaneous tissue disorders1/12
Change in tasteGeneral disorders1/12
Increased appetiteMetabolism and nutrition disorders1/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Trospium Chloride Extended Release, 60 mg
Median68 (65 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Trospium Chloride Extended Release, 60 mg
Female7
Male5
08

Study locations

1 site
  • Glendale, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2009
First posted
Mar 18, 2009
Start
Apr 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Dec 19, 2011
Last update
Feb 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00863551
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Mar 18, 2009
Start date
Apr 2009
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Dec 19, 2011
Last update
Feb 26, 2016

Study contacts

Medical Director
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trospium chloride

Start the discussion